Carcinosarcoma

Summary

Carcinosarcoma (MONDO:0002928) is a disease and 15 clinical trials. Top therapeutic interventions include carboplatin, zanidatamab, and cediranib. A subtype of malignant mixed neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	carcinosarcoma
Mondo ID	MONDO:0002928
MeSH	D002296
DOID	DOID:4236
NCIT	C34448
UMLS	C0007140
MedGen	2876
GARD	0006966
Is cancer (heuristic)	no

Also known as: carcinosarcoma · carcinosarcoma, malignant · malignant mixed mesodermal (mullerian) tumour · malignant mixed Mullerian tumour · mesodermal mixed tumor (morphologic abnormality) · mesodermal mixed tumour · mesodermal mixed tumour (morphologic abnormality) · mixed mesodermal (mullerian) tumour · mixed Mullerian tumor · mixed Mullerian tumour · mixed tumor, Mullerian · mullerian mixed tumor (morphologic abnormality) · mullerian mixed tumour · mullerian mixed tumour (morphologic abnormality)

Disease family

This is a subtype of malignant mixed neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant mixed neoplasm › carcinosarcoma

Related subtypes (14): carcinoma ex pleomorphic adenoma, uterine body mixed cancer, adenocarcinofibroma, ovarian seromucinous carcinoma, adenosarcoma, Wilms tumor, combined lung carcinoma, mixed lobular and ductal breast carcinoma, gonadoblastoma, anaplastic oligoastrocytoma, malignant mixed epithelial stromal tumor of the kidney, malignant phyllodes tumor, malignant vaginal mixed epithelial and mesenchymal neoplasm, adenoacanthoma

Subtypes (3): ovarian carcinosarcoma, fallopian tube carcinosarcoma, uterine carcinosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Carboplatin, Doxorubicin, Nivolumab, Olaparib, Pembrolizumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
Not specified	4
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT00502203	PHASE2	COMPLETED	Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
NCT00815945	PHASE2	COMPLETED	Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
NCT03241745	PHASE2	COMPLETED	A Study of Nivolumab in Selected Uterine Cancer Patients
NCT03395080	PHASE2	COMPLETED	A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
NCT03570437	PHASE2	UNKNOWN	Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
NCT03933761	PHASE2	WITHDRAWN	Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
NCT04513665	PHASE2	COMPLETED	ZW25 in Women With Endometrial Cancers
NCT05265793	PHASE2	UNKNOWN	Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
NCT05542407	PHASE1	RECRUITING	ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
NCT05252416	PHASE1	TERMINATED	(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT04122872	Not specified	RECRUITING	GISAR German Interdisciplinary Sarcoma Registry
NCT04458597	Not specified	COMPLETED	Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
NCT04681248	Not specified	NO_LONGER_AVAILABLE	Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
NCT04688749	Not specified	TERMINATED	Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CARBOPLATIN	4	3
ZANIDATAMAB	4	1
CEDIRANIB	3	1
DORDAVIPRONE	3	1
PAMIPARIB	3	1
DKN-01	2	2
CERTOCICLIB	1	1
CHEMBL3919533	0	1